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Abstract
 
Somatic hypermutation (SHM) and class switch recombination (CSR) are initiated by activation-
induced cytidine deaminase–mediated cytidine deamination of immunoglobulin genes. MutS
homologue (Msh) 2
 
 
 
/
 
 
 
 mice have reduced A-T mutations and CSR. This suggests that Msh2
may play a role in repairing activation-induced cytidine deaminase–generated G-U mismatches.
However, because Msh2 not only initiates mismatch repair but also has other functions, such as
signaling for apoptosis, it is not known which activity of Msh2 is responsible for the effects
observed, and consequently, many models have been proposed. To further dissect the role of
Msh2 in SHM and CSR, mice with a “knockin” mutation in the 
 
Msh2
 
 gene that inactivates
the adenosine triphosphatase domain were examined. This mutation (i.e., Msh2G674A),
which does not affect apoptosis signaling, allows mismatches to be recognized but prevents
Msh2 from initiating mismatch repair. Here, we show that, similar to Msh2
 
 
 
/
 
 
 
 mice, SHM in
Msh2
 
G674A
 
 mice is biased toward G-C mutations. However, CSR is partially reduced, and
switch junctions are more similar to those of postmeiotic segregation 2
 
 
 
/
 
 
 
 mice than to
Msh2
 
 
 
/
 
 
 
 mice. These results indicate that Msh2 adenosine triphosphatase activity is required
for A-T mutations, and suggest that Msh2 has more than one role in CSR.
Key words: activation-induced cytidine deaminase • mismatch repair • afﬁnity maturation • 
B cell • antibody
 
Introduction
 
High affinity antibodies of different classes are required to
efficiently neutralize and clear pathogens and toxins from
an animal’s circulation. Affinity maturation is achieved by
the somatic hypermutation (SHM) of immunoglobulin
variable regions followed by selection in germinal centers
for B cells producing high-affinity antigen-specific antibodies.
Changes in antibody class are mediated by the class switch
recombination (CSR) process, which recombines the V
region to a downstream constant region in the immuno-
globulin locus (1–3). Both processes require activation-
induced cytidine deaminase (AID; references 4, 5). AID
initiates SHM and CSR by deamination of cytidines in
the V region and switch regions, respectively (6–10).
Transcription of these sequences is expected to produce
single-stranded DNA that would allow access to AID for
deamination (6, 7, 11–13). This model for AID function is
supported by findings that mice deficient for the uracil
DNA glycosylase UNG have defects in both SHM and
CSR (14). The uridine that is thus created by deamination
is either replicated to produce T mutations or converted
into an abasic site by the uracil DNA glycosylase, UNG.
These abasic sites can be acted on by apurinic endonuclease
and repaired by base excision repair.
Although this model might account for mutations at G-C
basepairs, it does not explain how mutations occur at A-T
basepairs. Papers investigating mismatch repair (MMR)–
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deficient mice suggest that this pathway is responsible for in-
troducing mutations at A-T basepairs; mice deficient in
MutS homologue (Msh) 2 or Msh6 have fewer A-T muta-
tions than controls (15–18). These findings led to the hy-
pothesis that SHM proceeds in two phases as follows: the
first phase introduces mutations at G-C basepairs whereas
the second phase, which is Msh2/6-dependent, is responsi-
ble for mutations at A-T basepairs (16). However, it remains
unclear why the MMR system is mutagenic in B cells. One
possibility is that Msh2/6 heterodimers participate directly in
SHM by competing with UNG to bind to the AID-gener-
ated G-U mismatches, excising the DNA surrounding the
mismatch and initiating error-prone repair with the transle-
sional error-prone polymerases 
 
 
 
, 
 
 
 
, and 
 
 
 
 (11). However, it
has also been proposed that the defect in SHM and CSR in
Msh2
 
 
 
/
 
 
 
 mice is indirect and is due to reduced B cell viabil-
ity resulting from a general loss of genomic stability (19, 20).
This was supported by the finding in Msh2
 
 
 
/
 
 
 
 mice that
Peyer’s patch B cells that had undergone many rounds of
replication had increased microsatellite instability and the
germinal centers in such mice were small and showed in-
creased apoptosis (19, 20). Thus, these findings suggest that
programmed cell death might influence the outcome of
SHM. Indeed, SHM in Msh2
 
 
 
/
 
 
 
 mice occurs at a reduced
rate (16, 20), consistent with the notion that mutations do
not accumulate in Msh2
 
 
 
/
 
 
 
 mice because of reduced B cell
viability. However, if MMR is directly involved in produc-
ing A-T mutations during SHM, a reduced mutation fre-
quency would also be expected in Msh2
 
 
 
/
 
 
 
 mice.
After Msh2/6 heterdimers bind to mismatches, the aden-
osine triphosphatase (ATPase) domain of Msh2 processes
ATP (21). This is thought to induce a change in the Msh2/6
heterodimer that allows it to activate MMR and recruit
downstream repair factors such as the MutL homologue
(Mlh) 1, postmeiotic segregation (Pms) 2, and exonuclease 1
(21, 22). The ATPase domain of Msh2 contains a Walker
“type A” motif (i.e., GNNNNGKS/T), which is found in
other proteins involved in ATP hydrolysis and is known to
be involved in binding to the phosphate group of ATP (see
Fig. 1 A). Mutations in ATP processing domains occur fre-
quently in hereditary nonpolyposis colorectal cancer (23)
and result in MMR-deficient 
 
Saccharomyces cerevisiae
 
 (24,
25). Mice with a knockin mutation in the 
 
Msh2
 
 gene that
converts a glycine to an alanine at residue 674 (i.e.,
Msh2
 
G674A
 
 mice) in the Walker type A motif (i.e.,
GNNNNAKS/T) express normal amounts of the mutant
protein, are MMR deficient, and prone to B and T cell
lymphomas and gastrointestinal adenocarcinomas (un-
published data). Although an 
 
S. cerevisiae
 
 Msh2 protein
with a mutation in the equivalent residue to the mouse
Msh2G674A functions as a dominant-negative (24, 25), this
appears not to be the case for the murine Msh2G674A pro-
tein because mice heterozygous for the 
 
Msh2G674A
 
 muta-
tion were essentially normal. In vitro studies showed that
Msh2
 
G674A
 
/Msh6 heterodimers bound to G-G mismatches,
but were MMR deficient (unpublished data). However,
unlike Msh2
 
 
 
/
 
 
 
 mouse embryo fibroblasts, wild-type and
Msh2
 
G674A
 
 mouse embryo fibroblasts cells were sensitive to
 
cisplatin-induced apoptosis, indicating that Msh2
 
G674A
 
 re-
tains the ability to signal for this process (unpublished data).
The apoptotic signaling function of Msh2 is likely related to
its role in the S-phase checkpoint (26), where it acts as a
“damage sensor” possibly through a large complex that con-
tains checkpoint kinase CHK2 and ATM (23, 26).
Because the Msh2
 
G674A
 
 protein retains the apoptosis sig-
naling capacity of Msh2, but is defective in initiating
MMR, the G674A mutation represents a separation of
function mutation for the Msh2 protein. Therefore, we ex-
amined Msh2
 
G674A
 
 mice for defects in SHM and CSR be-
cause the repair activity of MMR is hypothesized to be
responsible for introducing mutations at A-T basepairs (de-
scribed in a previous paragraph) and might also be required
for CSR.
 
Materials and Methods
 
Mice and Immunizations. 
 
The Msh2
 
G674A
 
 mice were created
by a knockin targeting strategy and will be reported elsewhere
(unpublished data). Msh2
 
G674A
 
 were backcrossed to C57Bl/6 mice
for four generations and were housed in a pathogen-free facility.
Two Msh2
 
G674A
 
, two heterozygote littermates, and two wild-type
littermates that were 
 
 
 
70 d old were immunized by intraperito-
neal injections of alum-precipitated nitrophenyl (NP) coupled to
chicken 
 
 
 
 globulin (NP)
 
23
 
-CGG and sera was monitored for anti-
bodies specific to NP by ELISA, as described previously (27).
 
PCR Amplification and Sequence Analysis. 
 
The JH3–JH4 re-
gion was sequenced as described previously (27). In brief, Peyer’s
patches were harvested from three Msh2
 
G674A
 
 mice, three litter-
mate controls, and one Msh2
 
 
 
/
 
 
 
 mouse that were 
 
 
 
8 mo old.
PNA
 
hi
 
 B cells were FACS
 
®
 
 sorted. The JH3–JH4 region was am-
plified using Pfu turbo (Stratagene) and primers described previ-
ously (27). PCR products were cloned and sequenced. Statistics
for data in Table I were calculated using the paired Student’s 
 
t
 
test comparing individual mice grouped into control and
Msh2
 
G674A
 
 mice.
 
In Vitro Switching Assay. 
 
Switching was induced as described
previously (27). In brief, unimmunized 
 
 
 
6-mo-old mice were
killed, spleens were harvested, and B cell splenocytes were puri-
fied. B cells were plated in RPMI 1640 media containing 10%
FCS and 50 
 
 
 
g/ml LPS (Sigma-Aldrich) or with 50 
 
 
 
g/ml LPS
and 50 ng/ml rIL-4 (R&D Systems) for 4 d, and cells were har-
vested and stained with anti-IgG1 or anti-IgG3 FITC (BD Bio-
sciences) and anti-IgM CY5 (Jackson Immunochemicals). Cells
were washed with PBS, fixed with 1% paraformaldehyde in PBS,
and analyzed with a FACSCalibur™ (Becton Dickinson) appara-
tus. FACS
 
®
 
 analysis was performed using the FlowJo software
package (Treestar). Cells were gated for viability based on the for-
ward- and side-scatter profiles. The IgG-positive population was
scored according to the gating profile shown in Fig. 3. Statistics
were calculated using the paired Student’s 
 
t
 
 test comparing indi-
vidual mice grouped into control and Msh2
 
G674A
 
 mice.
 
S
 
 
 
-S
 
 
 
3 Switch-junction Analysis. 
 
Three Msh2
 
G674A
 
 and four
littermate controls were used in this analysis. Genomic DNA was
isolated using the DNAeasy kit (QIAGEN) from cells stimulated
with 50 
 
 
 
g/ml LPS. S
 
 
 
-S
 
 
 
3 junctions were amplified by PCR
using Expand Long Template Taq Polymerase (Roche) essentially
as described previously (28). The primers used are as follows: 
 
 
 
3-
H3, 5
 
 
 
-AACAAGCTTGGCTTAACCGAGATGAGCC-3
 
 
 
; and
 
 
 
3–2, 5
 
 
 
-TACCCTGACCCAGGAGCTGCATAAC-3
 
 
 
. Ampli-T
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fied PCR products were cloned using the TOPO cloning kit (In-
vitrogen). Plasmid DNA was prepared using a 96-well miniprep
kit (Millipore). T3 or T7 primers (Invitrogen) were used to se-
quence the PCR inserts. Sequence alignments were constructed
by comparing the PCR sequence with S
 
 
 
 references AF446347
and S
 
 
 
3 reference Musighana using Blast2 alignment (National
Center for Biotechnology Information). Although sometimes
there was more than one possible alignment due to the repetitive
nature of the switch regions, the regions with the largest homol-
ogy and highest identity were used. Statistics for data in Table II
were calculated using the Student’s 
 
t
 
 test, conditional on not hav-
ing insertions. Based on homologies falling into each group and
given weights due to the ordinal nature, this distribution was com-
pared for each mouse between mutant and control mice.
 
Proliferation Assays. 
 
5 
 
 
 
 10
 
5
 
 total spleen cells were plated, as
5-well replicates in a 96-well culture plate, in 200 
 
 
 
l final volume
of appropriate media. Three conditions were tested in these assays
as follows: unstimulated, LPS stimulation, and LPS 
 
 
 
 IL-4 stimu-
lation (same concentrations as described in the In Vitro Switching
Assay section). Proliferation assays were performed on day 3 by
pulsing with 1 
 
 
 
Ci/well of [
 
3
 
H]Thymidine (NEN Life Science
Products) for 
 
 
 
16 h before harvesting onto 96-well printed fil-
termats (Wallac) and measuring radioactive incorporation on an
LSC plate counter (model 1450; Microbeta; Wallac).
 
Online Supplemental Material.
 
In Fig. S1, 
 
 
 
-
 
 
 
3 switch junc-
tions from LPS-induced B cells are shown. In this figure, regions
of homology between 
 
 
 
 and 
 
 
 
3 switch regions and insertion se-
quences in 
 
 
 
-
 
 
 
3 switch junctions are detailed. Fig S1 is available
at http://www.jem.org/cgi/content/full/jem.20030880/DC1.
 
Results
 
Mice harboring a point mutation in the ATPase domain
of the 
 
Msh2
 
 gene were created by homologous recombina-
tion into the Msh2 loci. This mutation converts a glycine
to an alanine at residue 674 of the Msh2 protein (i.e.,
Msh2
 
G674A
 
; Fig. 1 A). An equivalent mutation in the 
 
Msh2
 
gene of 
 
S. cerevisiae
 
 inhibits Msh2 ATP processing (24, 25).
This defect was biochemically confirmed for murine
Msh2G674A (unpublished data).
Msh2
 
 
 
/
 
 
 
 mice show impaired antigen-specific humoral
responses (15, 16, 29). This deficiency is probably due to
defects in both the SHM and CSR processes. To deter-
mine whether Msh2
 
G674A
 
 mice are defective in either of
these processes, two heterozygous littermates and two
Msh2
 
G674A
 
 mice were immunized with the NP hapten cou-
pled to chicken 
 
  
 
globulin. Sera were analyzed 10 d later
by ELISA using NP
 
2
 
-BSA– and NP
 
17
 
-BSA–coated plates
that bind to high affinity and total NP-specific IgG, respec-
tively (27, 30). As shown in Fig. 1 B, NP-immunized
Msh2
 
G674A
 
 mice had approximately fivefold lower titers of
high affinity and total NP-specific IgG1 than did the het-
erozygous littermate controls. The antibody titers to NP in
wild-type and heterozygous littermates were similar (un-
published data). These results suggest that there is a defect
in SHM and/or CSR in Msh2
 
G674A
 
 mice.
To determine whether SHM was compromised in
Msh2
 
G674A
 
 mice, the JH3 and JH4 exons and flanking in-
trons in the heavy chain immunoglobulin locus were se-
quenced from FACS
 
®
 
-sorted PNA
 
Hi
 
 Peyer’s patch B cells
 
from three 
 
 
 
8-mo-old Msh2
 
G674A
 
 mice and three litter-
mate controls. Numerous studies have analyzed this region
to assess the effects of genetic deficiencies on the SHM
process because mutations are unselected and occur at high
rates (14, 17, 20, 27). One Msh2
 
 
 
/
 
  mouse was also exam-
ined as a positive control for effects on the SHM spectrum.
For each mouse, only unique mutations were tabulated. An
analysis of the characteristics of mutations identified re-
vealed that  42 and 82% of mutations occurred at G-C
basepairs in control and Msh2 /  mice, respectively (Fig. 2
A and Table I). This finding is consistent to what has been
reported previously for Msh2 /  mice (15, 16). Sequence
analysis of the Msh2G674A mice showed a similar defect in
SHM to Msh2 /  mice:  85% of mutations occurred at
G-C basepairs (Fig. 2 A and Table I). This defect likely re-
flects a deficiency in A-T mutations rather than an increase
in G-C mutations because the mutation frequency is lower
in Msh2G674A mice than in littermate controls (Fig. 2 B and
Table I; see Discussion). Mutation frequencies may not be
comparable between normal controls of the Msh2G674A and
Msh2 /  mice because they were not littermates, although
Figure 1. The Msh2G674A mutation leads to a reduced anti-NP
immunoglobulin response in Msh2G674A mice. (A) Schematic illustrating
the domains of murine Msh2. Shown is the DNA binding domain, the
domains involved in binding to Msh3 and Msh6, and the ATPase domain,
which contains the Walker A motif. (B) Anti-NP titers in NP-immunized
mice. Two Msh2G674A mice (M/M) and two heterozygous littermate
controls (M/ ) were immunized i.p. with NP23-CGG. ELISA plates
coated with NP2-BSA or NP17-BSA were used to measure the serum titers
of high affinity and total NP-specific IgG1, respectively. Serum titers
were calculated using the serial dilution closest to 1/2 maximum. Standard
errors are shown.T
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they were age-matched and analyzed at the same time.
Mutations at RGYW/WRCY hotspot motifs were also in-
creased in Msh2G674A mice (Table I, 16 vs. 32% in control
and Msh2G674A mice, respectively) and many of these base
changes were transition mutations (Table I). Msh2 /  mice
also showed a similar increase in hotspot and transition mu-
tations to Msh2G674A mice (Table I). These findings show
that SHM is similarly affected in Msh2 /  and Msh2G674A
mice, indicating that the repair activity initiated by Msh2 is
required for A-T mutations in SHM.
The decreased titers to the NP-hapten could also be due
to defects in the CSR process. To investigate this issue, B
cell splenocytes from three Msh2G674A mice, seven littermate
controls, and two age-matched Msh2 /  mice were isolated
(Materials and Methods) and stimulated in culture with LPS
or LPS and IL-4. LPS stimulates primary B cells to undergo
CSR from IgM to IgG3, whereas LPS and IL-4 induces
CSR to IgG1 (Fig. 3, A and B). CSR to IgG1 was reduced
 35% in Msh2 /  B cells and  25% in Msh2G674A B cells
(Fig. 3, A and B, left). However, CSR to IgG3 was more
severely affected in Msh2 /  and Msh2G674A B cells (Fig. 3,
A and B, right) as follows: Msh2G674A B cells showed an
 50% reduction in CSR to IgG3 whereas Msh2 /  B cells
showed an  80% reduction when compared with wild-
type B cells (Fig. 3, A and B, right). No significant differ-
ences were observed in the proliferative capacity of B cells
from control, Msh2G674A, and Msh2 /  mice (Fig. 3 C),
consistent with a previous paper (31). Thus, deficiencies in
CSR activity in Msh2G674A and Msh2 /  B cells could not
be ascribed to differences in proliferation. Collectively,
these data indicate that the CSR process is affected in
Msh2G674A mice, albeit not as severely as in Msh2 /  mice.
Previous works showed that the junctions of  - 3
switch regions were altered in Msh2 /  B cells (28, 32).
Short regions of microhomology between   and  3 switch
regions are typically observed in a large proportion of
switch junctions from normal B cells. However, in Msh2 / 
B cells, fewer switch junctions contain short regions of
Figure 2. Skewed SHM in Msh2G674A mice. (A) Sequencing analysis of
the JH3-JH4 region in Peyer’s patch B cells from Msh2 /  mice,
Msh2G674A mice (M/M), and homozygous ( / ) or heterozygous ( /M)
wild-type littermate controls. Unique mutations that occurred at the nucle-
otides depicted on the left column were mutated to the nucleotides
shown in each row. The top three panels represent compiled data from
one Msh2 / , three Msh2G674A, and three littermate controls (Table I).
The bottom six panels represent data derived from each individual
Msh2G674A and littermate control mice. (B) Pie charts depict the distribution
of mutation frequencies for plasmid clones that were sequenced (center of
pie) from each mouse group and the proportion of sequences with 0, 1, 2
. . .  mutations (numbers of mutations outside the pie slices).
Figure 3. Reduced in vitro switching of purified Msh2G674A B cells.
(A) (left) B cell switching induced with LPS and IL-4. Representative
FACS® profile of experiment showing the percent of IgG1 and IgG3
positive cells of the gated live population of B cells derived from wild-
type ( / ) and Msh2G674A (M/M) mice. (right) Same, except that B cell
switching was induced with LPS. (B) Means of switching experiment of
B cells derived from three wild-type ( / ), four heterozygous
Msh2G674A ( /M), three homozygous Msh2G674A (M/M), and two homozy-
gous Msh2 /  ( / ) mice. Because of the high degree of variability
between switching experiments, the data are normalized to percent
maximum switching for each experiment. Standard errors are shown.
*, P   0.05 when compared with  /M controls. (C) B cell proliferation
in control, Msh2G674A, and Msh2 /  B cells. Thymidine incorporation on
day 3 of unstimulated B cells, or B cells stimulated with LPS or LPS and
IL4. M/M are homozygous Msh2G674A B cells, whereas  /  are homozy-
gous Msh2 /  B cells. Standard errors are shown.T
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microhomologies (28). Although the significance of these
findings to the CSR process is not clear, it suggests that mi-
crohomologies help resolve DNA breaks in an Msh2-
dependent manner during normal CSR. To further inves-
tigate the CSR process in Msh2G674A mice,  - 3 switch
junctions were analyzed in LPS-stimulated, control, and
Msh2G674A B cells. Two other groups have performed
switch-junction analysis in MMR-deficient mice (28, 32).
Therefore, we have tabulated the switch junctions so that
comparisons can be made between our data and those of
the other two groups.
Three Msh2G674A mice and four littermate controls were
used in this analysis and only unique switch junctions were
tabulated (i.e., 58 and 54 sequences for Msh2G674A and
controls, respectively). The complete dataset is shown in
Fig. S1 available at http://www.jem.org/cgi/content/full/
jem.20030880/DC1 and summarized in Table II. The
switch junctions from Msh2G674A B cells differed in two
ways from those of controls. First, more sites of recombi-
nation had longer microhomologies between the   and  3
in Msh2G674A B cells than in controls as follows: 24% of
switch junctions from Msh2G674A B cells had microhomol-
ogies that were  5 nucleotides long compared with only
9% in littermate controls (Table II). Although Schrader et
al. reported that only 3% of switch junctions from wild-
type mice had  5 nucleotide-long microhomologies (28),
they reported that  23% of switch junctions from Pms2 / 
and Mlh1 /  B cells and 0% of switch junctions from
Msh2 /  B cells had  5 nucleotide-long microhomolo-
gies (28). Thus, switch junctions from Msh2G674A B cells
are more similar to those found in Pms2 /  and Mlh1 / 
B cells. Ehrenstein et al. reported that the mean length of
uninterrupted donor/acceptor sequence in Pms2 /  and
control B cells is 3.5 and 0.8, respectively (32). Analyzing
our data in that manner showed a mean length of uninter-
rupted donor/acceptor sequence from Msh2G674A and con-
trol B cells to be 2.6 and 1.8, respectively. Thus, the trend
of longer microhomologies in Msh2G674A B cells was again
observed, albeit not as pronounced as in Pms2 /  B cells.
Therefore, switch junctions from Msh2G674A B cells are less
like those in Msh2 /  B cells and more similar to those in
Pms2 /  and Mlh1 /  B cells.
The second difference that was observed in this analysis
was that 15% of the switch junctions in Msh2G674A B cells
had large insertions compared with only 2% in control B
cells (Table II). Most of these insertions were  24 basepairs
long, but two were large and included sequences from a
murine type C retrovirus (222 nucleotides) and a segment
from chromosome 2 (114 nucleotides; Fig. S1). Although it
is difficult to rule out the possibility that these two large in-
sertions were not generated by a PCR artifact, large in-
sertions, including some with viral sequences, have been
Table I. SHM of the Immunoglobulin JH3-JH4a Region in Peyer’s Patch B Cellsb
Controls Msh2G674A Msh2 / 
Mutation frequency ( 10 3)c 126/73,690 (1.71) 115/158,580 (0.63) 90/53,300 (1.69)
GC mutations/total 53/126 (42%) 98/115 (85%)e 74/90 (82%)
Transition mutations/total 69/126 (55%) 84/115 (73%)e 56/90 (62%)
Hotspot mutationsd/total 20/126 (16%) 38/115 (32%)e 23/90 (26%)
aThe JH2 to JH4 region is 1,460 bp long of which 1,300 bp was sequenced. Data obtained from Fig. 2.
bPCR products amplified by PFU polymerase were cloned and plasmids sequenced. Identical mutations that were observed in more than one plas-
mid for each mouse were scored only once.
cFrequency is defined as mutations per basepair sequenced.
dHotspot mutations occur in G-C basepairs within RGYW or WRCY motifs. 31/650 nucleotides (4.8%) of the JH3–JH4 region are hotspot nucleotides.
eP   0.05 compared to controls using the paired Student’s t test.
Table II. Summarya of  - 3 Switch Junctions from LPS-stimulated B Cellsb
Microhomologies Insertions
Blunt 1–2 nt 3–4 nt  5 nt 1–4 nt  5 nt Total
Controls (%) 16 (30) 21 (39) 6 (11) 5 (9) 5 (9) 1 (2) 54 (100)
Msh2G674A (%)c 10 (17) 12 (20) 9 (15) 14 (24) 5 (8) 9 (15) 59 (100)
aData presented in Fig. S1.
bUnique switch junctions compiled from three Msh2G674/G674A mice and four littermate controls.
cMicrohomology lengths are statistically different when compared with controls (P   0.04). See Materials and Methods.
nt, nucleotide.T
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observed in DNA rearrangements in immune and nonim-
mune cells (33). In addition, an increase in nucleotide in-
sertions was also observed in Msh2 /  B cells (28). This in-
dicates that switch junctions from Msh2G674A B cells have a
mixed phenotype exhibiting similarities to switch junctions
from Pms2 / /Mlh1 /  mice and from Msh2 /  B cells.
Collectively, these data show that CSR is perturbed in
Msh2G674A mice, but in a manner that is distinct from
Msh2 /  mice.
Discussion
Although AID initiates SHM and CSR by cytidine
deamination of single-stranded DNA in the V region and
switch regions, respectively, the subsequent events are
likely to be quite different because proteins involved in
nonhomologous end joining, such as Ku70 and Ku80, are
required for CSR and not for SHM (34, 35). However,
Msh2 has been found to be involved in both SHM and
CSR, implying that these two processes might have other
similarities. What complicates this interpretation is that
Msh2 functions in at least three distinct physiological pro-
cesses and, thus, might utilize a different function (or com-
bination of functions) depending on the type of DNA
lesion it encounters. Msh2 has been found to repair
mismatches caused by point mutations or small insertions
or deletions, to signal apoptosis in cells in response to
DNA damage, and to inhibit recombination between
nonidentical sequences (21). The goal of this paper was to
dissect the activities of Msh2 and determine their require-
ment for SHM and CSR. The Msh2G674A mutation,
which is located within the ATPase domain of Msh2, dis-
rupts ATP binding and/or hydrolysis (24, 25; unpublished
data). As a result, the Msh2G674A protein lacks the ability
to initiate repair of mismatched DNA, but retains the
apoptosis-inducing function of Msh2. It is not known
whether Msh2G674A can function to inhibit recombina-
tion between nonidentical sequences. Thus, at least two
functions for the Msh2 protein have been dissociated by
the G674A mutation.
The findings reported here show that SHM is compro-
mised in Msh2G674A mice in two ways. First, the majority
of mutations occur at G-C basepairs (Table I). Second, the
mutation frequencies are lower in Msh2G674A mice than in
littermate controls. The preferential mutation of G-C base-
pairs is also seen in Msh2 /  mice (15, 16) but is not as
dramatic in Pms2 /  and Mlh1 /  mice (15, 32, 36–38),
suggesting that Pms2 or Mlh1 is partially redundant. The
findings reported here also suggest that the repair of mis-
matches, which is deficient in Msh2G674A mice, is required
for A-T mutations. Thus, Msh2/6 heterodimers might
bind to AID-generated G-U mismatches, a mismatch that
can be recognized by Msh2/6 heterodimers (39), and ini-
tiate error-prone repair. Although it is unclear how Msh2-
directed repair can lead to mutations at A-T basepairs, one
possibility is that the DNA surrounding the mismatch is
excised and the resulting gap is filled in by the translesional
error-prone polymerases  ,  , and   that have been impli-
cated in SHM (40–46). In fact, polymerase   has been im-
plicated as being the A-T mutator in SHM (42, 43). Such a
proposition would suggest that secondary mutations intro-
duced by these error-prone polymerases might trigger a
second round of MMR because their activities would be
expected to produce additional novel substrates for Msh2/6
heterodimers.
The lower mutation frequencies observed in Msh2G674A
mice could simply reflect a loss of mutations at A-T base-
pairs. Indeed, adding back the A-T mutations that were
calculated to have been lost in Msh2G674A mice would give
a mutation frequency of 1.47   10 3 (i.e., 98 G-C muta-
tions in Msh2G674A mice divided by 42% G-C mutations in
littermates would give 233 total mutations in 15,8580 base
pairs sequenced; Table I), which is similar to that of the lit-
termate controls (Table I, 1.71   10 3). Conversely, this
lower mutation frequency is consistent with the hypothesis
that fewer mutations accumulate in Msh2G674A B cells be-
cause of reduced B cell viability (19, 20). In this scenario,
the effects of Msh2 deficiency on SHM would be an indi-
rect consequence of a general defect in DNA repair. This
issue was partially addressed with findings that SHM in
Msh2 /  mice transgenic for the bcl-2 oncogene was simi-
lar to Msh2 /  mice (47), showing that programmed cell
death does not contribute significantly to SHM effects.
However, in contrast to the work presented here and those
of others (15, 16), that analysis did not find a significant
skewing of mutations toward G-C basepairs in Msh2 / 
and bcl 2-transgenic Msh2 /  mice when compared with
controls (47). Nevertheless, it is possible that SHM in
Msh2G674A mice is skewed due to a reduced overall muta-
tion frequency coupled with an increase in mutations at G-C
basepairs. The increase in G-C mutations might be the
result of preferential repair of G-U mispairs by Msh2/6
heterodimers over other mispairs (15, 48). Thus, the re-
duced A-T mutations in Msh2 /  and Msh6 /  mice
would be a consequence of MMR deficiency, and would
possibly indicate that A-T mutations occur independent of
Msh2. However, the results presented here add further
support to the notion that Msh2/6 dimers directly partici-
pate in the SHM process because Msh2G674A mice still show
a bias toward mutating G-C basepairs, even though the
Msh2G674A protein retains a normal capacity to signal
apoptosis, a process that was deficient in Msh2 /  mice.
CSR in Msh2G674A mice was also perturbed in two ways.
First, CSR activity was reduced in Msh2G674A B cells
compared with controls, albeit, not to the same degree as
in Msh2 /  B cells (Fig. 3). This indicates that the
Msh2G674A protein retains some activities that allow CSR
to proceed at a reduced capacity. Second,  - 3 switch
junctions in Msh2G674A B cells were altered when com-
pared with controls; a larger proportion of switch junctions
from Msh2G674A B cells contained long microhomologies
and large insertions when compared with normal controls
(Table II). Although large insertions were also observed in
Msh2 /  B cells (28), long microhomologies were ob-T
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served in Mlh1 /  and Pms2 /  B cells (28, 32) and not in
Msh2 /  B cells (28). Thus, switch junctions in Msh2G674A
mice display a mixed phenotype between Msh2 /  and
Pms2 /  or Mlh1 /  mice. And because Msh2G674A B cells
have more CSR activity than Msh2 /  B cells (Fig. 3),
these data suggest that Msh2 has more than one role in
CSR, one (or more) that is ATPase dependent and one (or
more) that is ATPase independent. However, we cannot
exclude the possibility that one of these roles is not directly
involved in the CSR process.
The data presented here suggest that DNA lesions pro-
duced during CSR are repaired by a number of indepen-
dent mechanisms. At least two pathways appear to be Msh2
dependent, whereas one or more are Msh2 independent.
The latter is inferred because CSR still proceeds at signifi-
cant levels in MMR-deficient mice. The similarity in CSR
activity between Msh2G674A and Pms2 /  or Mlh1 /  mice
might be due to the uncoupling of Pms2/Mlh1 function
from Msh2 by the Msh2G674A mutation. Therefore, the
difference between Msh2 /  and MshG674A might reveal a
pathway that is Pms2/Mlh1 independent. This notion is
supported by findings in S. cerevisiae that Msh2 functions
with Msh3 and Rad1 in an Mlh1–Pms2-independent path-
way to remove 3  overlaps during gene conversion (49).
Indeed, Msh2 was suggested recently to have more than
one role in CSR because switch junctions from mice dou-
bly deficient in Mlh1 and Msh2 are intermediate to switch
junctions from the singly deficient mice (50), similar to that
of Msh2G674A mice. But because the phenotype of these
Mlh1/Msh2 doubly deficient mice was not similar to
Msh2 /  mice, which would be expected if Msh2 acted
upstream of Mlh1, the authors concluded that Mlh1 func-
tions either upstream of Msh2 or functions independently
of Msh2 (50). However, it is interesting to note that the
Msh2G674A mutation produced a CSR phenotype that
was similar to Mlh1/Msh2 doubly deficient mice, suggest-
ing that Msh2 is dominant or functions independently of
Mlh1. Although the work reported here does not fully re-
solve the questions about whether Msh2 and other MMR
proteins are directly or indirectly involved in either SHM
or CSR, the use of such mutated proteins should ultimately
lead to the dissection of the different roles of MMR in each
of these processes.
We would like to thank Dr. D. Ronai for critical review of the
manuscript and M. Fan for technical help. 
This work was supported by grants from the National Institutes
of Health to W. Edelmann (CA76329 and CA93484), to P.D.
Bardwell (grant 5T32 CA09173), and to M.D. Scharff (CA 72649,
CA102705, and AI 43937), who is also supported by the Harry Ea-
gle Chair provided by the National Women’s Division of the Al-
bert Einstein College of Medicine. Z. Li is a Cancer Research Insti-
tute Fellow. M.D. Iglesias-Ussel is a fellow of the Ministerio de
Educacion, Cultura y Deporte. A. Martin is a special fellow of the
Leukemia and Lymphoma Society.
Submitted: 29 May 2003
Revised: 14 August 2003
Accepted: 27 August 2003
References
1. Kenter, A.L. 2003. Class-switch recombination: after the
dawn of AID. Curr. Opin. Immunol. 15:190–198.
2. Manis, J.P., M. Tian, and F.W. Alt. 2002. Mechanism and con-
trol of class-switch recombination. Trends Immunol. 23:31–39.
3. Stavnezer, J. 2000. Molecular processes that regulate class
switching. Curr. Top. Microbiol. Immunol. 245:127–168.
4. Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shin-
kai, and T. Honjo. 2000. Class switch recombination and hyper-
mutation require activation-induced cytidine deaminase (AID),
a potential RNA editing enzyme. Cell. 102:553–563.
5. Revy, P., T. Muto, Y. Levy, F. Geissmann, A. Plebani, O.
Sanal, N. Catalan, M. Forveille, R. Dufourcq-Labelouse, A.
Gennery, et al. 2000. Activation-induced cytidine deaminase
(AID) deficiency causes the autosomal recessive form of the
Hyper-IgM syndrome (HIGM2). Cell. 102:565–575.
6. Bransteitter, R., P. Pham, M.D. Scharff, and M.F. Goodman.
2003. Activation-induced cytidine deaminase deaminates
deoxycytidine on single-stranded DNA but requires the ac-
tion of RNase. Proc. Natl. Acad. Sci. USA. 100:4102–4107.
7. Chaudhuri, J., M. Tian, C. Khuong, K. Chua, E. Pinaud, and
F.W. Alt. 2003. Transcription-targeted DNA deamination by
the AID antibody diversification enzyme. Nature. 422:726–
730.
8. Dickerson, S.K., E. Market, E. Besmer, and F.N. Papavasil-
iou. 2003. AID mediates hypermutation by deaminating sin-
gle stranded DNA. J. Exp. Med. 197:1291–1296.
9. Petersen-Mahrt, S.K., R.S. Harris, and M.S. Neuberger.
2002. AID mutates E. coli suggesting a DNA deamination
mechanism for antibody diversification. Nature. 418:99–104.
10. Martin, A., P.D. Bardwell, C.J. Woo, M. Fan, M.J. Shulman,
and M.D. Scharff. 2002. Activation-induced cytidine deami-
nase turns on somatic hypermutation in hybridomas. Nature.
415:802–806.
11. Martin, A., and M.D. Scharff. 2002. AID and mismatch repair in
antibody diversification. Nat. Rev. Immunol. 2:605–614.
12. Ramiro, A.R., P. Stavropoulos, M. Jankovic, and M.C. Nus-
senzweig. 2003. Transcription enhances AID-mediated cyti-
dine deamination by exposing single-stranded DNA on the
nontemplate strand. Nat. Immunol. 4:452–456.
13. Yu, K., F. Chedin, C.L. Hsieh, T.E. Wilson, and M.R. Lieber.
2003. R-loops at immunoglobulin class switch regions in the
chromosomes of stimulated B cells. Nat. Immunol. 4:442–451.
14. Rada, C., G.T. Williams, H. Nilsen, D.E. Barnes, T.
Lindahl, and M.S. Neuberger. 2002. Immunoglobulin iso-
type switching is inhibited and somatic hypermutation per-
turbed in UNG-deficient mice. Curr. Biol. 12:1748–1755.
15. Phung, Q.H., D.B. Winter, A. Cranston, R.E. Tarone, V.A.
Bohr, R. Fishel, and P.J. Gearhart. 1998. Increased hypermu-
tation at G and C nucleotides in immunoglobulin variable
genes from mice deficient in the MSH2 mismatch repair pro-
tein. J. Exp. Med. 187:1745–1751.
16. Rada, C., M.R. Ehrenstein, M.S. Neuberger, and C. Mil-
stein. 1998. Hot spot focusing of somatic hypermutation in
MSH2-deficient mice suggests two stages of mutational tar-
geting. Immunity. 9:135–141.
17. Wiesendanger, M., B. Kneitz, W. Edelmann, and M.D.
Scharff. 2000. Somatic hypermutation in MutS homologue
(MSH)3-, MSH6-, and MSH3/MSH6-deficient mice reveals
a role for the MSH2-MSH6 heterodimer in modulating the
base substitution pattern. J. Exp. Med. 191:579–584.
18. Bertocci, B., L. Quint, F. Delbos, C. Garcia, C.-A. Reynaud,T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
Impaired Somatic Hypermutation and Isotype Switching in Msh2G674A Mice 1178
and J.-C. Weill. 1998. Probing immunoglobulin gene hyper-
mutation with microsatellites suggests a nonreplicative short
patch DNA synthesis process. Immunity. 9:257–265.
19. Vora, K.A., K.M. Tumas-Brundage, V.M. Lentz, A. Cran-
ston, R. Fishel, and T. Manser. 1999. Severe attenuation of
the B cell immune response in Msh2-deficient mice. J. Exp.
Med. 189:471–482.
20. Frey, S., B. Bertocci, F. Delbos, L. Quint, J.C. Weill, and C.A.
Reynaud. 1998. Mismatch repair deficiency interferes with the
accumulation of mutations in chronically stimulated B cells and
not with the hypermutation process. Immunity. 9:127–134.
21. Harfe, B.D., and S. Jinks-Robertson. 2000. DNA mismatch
repair and genetic instability. Annu. Rev. Genet. 34:359–399.
22. Tishkoff, D.X., A.L. Boerger, P. Bertrand, N. Filosi, G.M.
Gaida, M.F. Kane, and R.D. Kolodner. 1997. Identification
and characterization of Saccharomyces cerevisiae EXO1, a
gene encoding an exonuclease that interacts with MSH2.
Proc. Natl. Acad. Sci. USA. 94:7487–7492.
23. Heinen, C.D., C. Schmutte, and R. Fishel. 2002. DNA re-
pair and tumorigenesis: lessons from hereditary cancer syn-
dromes. Cancer Biol. Ther. 1:477–485.
24. Drotschmann, K., A.B. Clark, H.T. Tran, M.A. Resnick,
D.A. Gordenin, and T.A. Kunkel. 1999. Mutator phenotypes
of yeast strains heterozygous for mutations in the MSH2
gene. Proc. Natl. Acad. Sci. USA. 96:2970–2975.
25. Studamire, B., T. Quach, and E. Alani. 1998. Saccharomyces
cerevisiae Msh2p and Msh6p ATPase activities are both required
during mismatch repair. Mol. Cell. Biol. 18:7590–7601.
26. Brown, K.D., A. Rathi, R. Kamath, D.I. Beardsley, Q.
Zhan, J.L. Mannino, and R. Baskaran. 2003. The mismatch
repair system is required for S-phase checkpoint activation.
Nat. Genet. 33:80–84.
27. Bardwell, P.D., A. Martin, E. Wong, Z. Li, W. Edelmann,
and M.D. Scharff. 2003. Cutting edge: the G-U mismatch
glycosylase methyl-CpG binding domain 4 is dispensable for
somatic hypermutation and class switch recombination. J. Im-
munol. 170:1620–1624.
28. Schrader, C.E., J. Vardo, and J. Stavnezer. 2002. Role for
mismatch repair proteins Msh2, Mlh1, and Pms2 in immuno-
globulin class switching shown by sequence analysis of re-
combination junctions. J. Exp. Med. 195:367–373.
29. Ehrenstein, M.R., and M.S. Neuberger. 1999. Deficiency in
msh2 affects the efficiency and local sequence specificity of
immunoglobulin class-switch recombination: parallels with
somatic hypermutation. EMBO J. 18:3484–3490.
30. Takahashi, Y., P.R. Dutta, D.M. Cerasoli, and G. Kelsoe. 1998.
In situ studies of the primary immune response to (4-hydroxy-3-
nitrophenyl)acetyl. V. affinity maturation develops in two stages
of clonal selection. J. Exp. Med. 187:885–895.
31. Schrader, C.E., W. Edelmann, R. Kucherlapati, and J. Stav-
nezer. 1999. Reduced isotype switching in splenic B cells
from mice deficient in mismatch repair enzymes. J. Exp. Med.
190:323–330.
32. Ehrenstein, M.R., C. Rada, A.M. Jones, C. Milstein, and
M.S. Neuberger. 2001. Switch junction sequences in PMS2-
deficient mice reveal a microhomology-mediated mechanism
of Ig class switch recombination. Proc. Natl. Acad. Sci. USA.
98:14553–14558.
33. Roth, D.B., X.B. Chang, and J.H. Wilson. 1989. Compari-
son of filler DNA at immune, nonimmune, and oncogenic
rearrangements suggests multiple mechanisms of formation.
Mol. Cell. Biol. 9:3049–3057.
34. Casellas, R., A. Nussenzweig, R. Wuerffel, R. Pelanda, A.
Reichlin, H. Suh, X.F. Qin, E. Besmer, A. Kenter, K. Ra-
jewsky, and M.C. Nussenzweig. 1998. Ku80 is required for
immunoglobulin isotype switching. EMBO J. 17:2404–2411.
35. Manis, J.P., Y. Gu, R. Lansford, E. Sonoda, R. Ferrini, L.
Davidson, K. Rajewsky, and F.W. Alt. 1998. Ku70 is re-
quired for late B cell development and immunoglobulin
heavy chain class switching. J. Exp. Med. 187:2081–2089.
36. Winter, D.B., Q.H. Phung, A. Umar, S.M. Baker, R.E.
Tarone, K. Tanaka, R.M. Liskay, T.A. Kunkel, V.A. Bohr,
and P.J. Gearhart. 1998. Altered spectra of hypermutation in
antibodies from mice deficient for the DNA mismatch repair
protein PMS2. Proc. Natl. Acad. Sci. USA. 95:6953–6958.
37. Kim, N., G. Bozek, J.C. Lo, and U. Storb. 1999. Different
mismatch repair deficiencies all have the same effects on so-
matic hypermutation: intact primary mechanism accompa-
nied by secondary modifications. J. Exp. Med. 190:21–30.
38. Phung, Q.H., D.B. Winter, R. Alrefai, and P.J. Gearhart. 1999.
Hypermutation in Ig V genes from mice deficient in the MLH1
mismatch repair protein. J. Immunol. 162:3121–3124.
39. Gu, L., J. Wu, L. Qiu, C.D. Jennings, and G.M. Li. 2002.
Involvement of DNA mismatch repair in folate deficiency-
induced apoptosis. J. Nutr. Biochem. 13:355–363.
40. Poltoratsky, V., M.F. Goodman, and M.D. Scharff. 2000. Er-
ror-prone candidates vie for somatic mutation. J. Exp. Med.
192:F27–F30.
41. Poltoratsky, V., C.J. Woo, B. Tippin, A. Martin, M.F.
Goodman, and M.D. Scharff. 2001. Expression of error-
prone polymerases in BL2 cells activated for Ig somatic hy-
permutation. Proc. Natl. Acad. Sci. USA. 98:7976–7981.
42. Rogozin, I.B., Y.I. Pavlov, K. Bebenek, T. Matsuda, and T.A.
Kunkel. 2001. Somatic mutation hotspots correlate with DNA
polymerase eta error spectrum. Nat. Immunol. 2:530–536.
43. Zeng, X., D.B. Winter, C. Kasmer, K.H. Kraemer, A.R. Leh-
mann, and P.J. Gearhart. 2001. DNA polymerase eta is an
A-T mutator in somatic hypermutation of immunoglobulin
variable genes. Nat. Immunol. 2:537–541.
44. Zan, H., A. Komori, Z. Li, A. Cerutti, A. Schaffer, M.F. Flaj-
nik, M. Diaz, and P. Casali. 2001. The translesion DNA
polymerase zeta plays a major role in Ig and bcl-6 somatic hy-
permutation. Immunity. 14:643–653.
45. Diaz, M., L.K. Verkoczy, M.F. Flajnik, and N.R. Klinman.
2001. Decreased frequency of somatic hypermutation and
impaired affinity maturation but intact germinal center for-
mation in mice expressing antisense RNA to DNA polymer-
ase zeta. J. Immunol. 167:327–335.
46. Faili, A., S. Aoufouchi, E. Flatter, Q. Gueranger, C.A. Rey-
naud, and J.C. Weill. 2002. Induction of somatic hypermuta-
tion in immunoglobulin genes is dependent on DNA poly-
merase iota. Nature. 419:944–947.
47. Alabyev, B., and T. Manser. 2002. Bcl-2 rescues the germinal
center response but does not alter the V gene somatic hyper-
mutation spectrum in MSH2-deficient mice. J. Immunol. 169:
3819–3824.
48. Reynaud, C.A., B. Bertocci, S. Frey, F. Delbos, L. Quint,
and J.C. Weill. 1999. Mismatch repair and immunoglobulin
gene hypermutation: did we learn something? Immunol. To-
day. 20:522–527.
49. Paques, F., and J.E. Haber. 1997. Two pathways for removal of
nonhomologous DNA ends during double-strand break repair
in Saccharomyces cerevisiae. Mol. Cell. Biol. 17:6765–6771.
50. Schrader, C.E., J. Vardo, and J. Stavnezer. 2003. Mlh1 can
function in antibody class switch recombination indepen-
dently of Msh2. J. Exp. Med. 197: 1377–1383.